Our Sources
We don’t ask you to trust us — we show you our work. These are the 27 recognised authorities we draw information from, grouped by how much weight they carry in our evidence hierarchy. For any given claim, we cite the strongest source available, and we go to these primaries rather than summarising other websites.
What listing a source does and doesn’t mean
These organisations are sources we cite. Listing them here does not imply they endorse, review, or are affiliated with GLP-1 Healthcare. Any page that has been reviewed by a named clinician says so explicitly, with that person’s real credentials.
Regulatory & government
8 sourcesThe highest-authority sources for what a drug is approved to do, its labeled risks, and how it is covered. We treat these as the operational baseline.
Approval status, approved indications, boxed warnings, and MedWatch safety communications.
The official, current FDA-approved prescribing information (drug labels).
Diabetes, obesity, and metabolic-disease background from a government research body.
Plain-language patient drug and condition information.
Obesity and diabetes prevalence and surveillance data.
Professional societies & guidelines
8 sourcesConsensus clinical guidance from the bodies that set standards of care. We cite the guideline, its issuing body, and its publication year.
Clinical practice guidelines for hormonal and metabolic conditions.
Obesity-treatment algorithms and clinical guidance.
Endocrinology and obesity clinical guidelines.
GLP-1 guidance on gastrointestinal effects and peri-procedural use.
Guidance on holding GLP-1 medications before anesthesia.
Peer-reviewed literature & trials
6 sourcesPrimary evidence from the clinical trials and journals that establish efficacy and safety. We link the specific study and record its date.
Publisher of many of the pivotal GLP-1 efficacy and outcomes trials.
Pivotal metabolic-medicine trials and reviews.
The literature index we search to find and verify primary studies.
Trial registry — including the STEP, SUSTAIN, SELECT, SURPASS, SURMOUNT, and SURMOUNT-OSA programs we reference.
Manufacturer prescribing information
2 sourcesThe definitive source for approved dosing, indications, contraindications, and labeled adverse events — read as primary label data, not marketing.
Label data for Ozempic, Wegovy, Rybelsus, and Saxenda.
Reputable secondary references
3 sourcesUsed only to cross-check and orient — never as a sole source, and never in place of a primary citation.
Cross-checking patient-facing explanations against an established institution.
Peer-reviewed clinical reference summaries.
Notice something out of date?
Guidelines and labels change. If a source here has been superseded, or you think we should be citing something stronger, tell us and we’ll review it. See our Editorial Policy for how corrections work.